跳至主要内容
临床试验/NCT00247039
NCT00247039Unknown1 期

A Controlled Study to Determine The Clinical Efficacy Of Garlic Compounds In Patients With Chemotherapy Related Febrile Neutropenia

Hadassah Medical Organization1 个研究点 分布在 1 个国家目标入组 120 人开始时间: 2006年6月最近更新:
适应症

试验速览

阶段
1 期
入组人数
120
试验地点
1
主要终点
Time to fever and beginning of empiric antibiotic treatment.

研究概览

简要总结

To determine the clinical effects of garlic in preventing and treatment of patients with chemotherapy related febrile neutropenia.These patients have a very high incidence of infections which are not routinely covered by the standard empiric therapy. Adding a non- toxic and possibly effective therapy may reduce the risk for infections, synergize the empiric antibiotic treatment and may lessen the need for broader spectrum and more severe side effects.

详细描述

Patients eligible are randomized to receive placebo or garlic capsules after chemotherapy course and until leukocyte recovery.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Factorial
主要目的
Prevention
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
16 Years 至 —(Child, Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • FN patients expected to have at least 5 days or more of neutropenia will be eligible for treatment with garlic compounds AST/ALT ≤ 3 times the upper limit of institutional laboratory normal.
  • Total bilirubin ≤ 2 times the upper limit of institutional laboratory normal.
  • BUN and creatinine should be ≤ 3 times the upper limit of institutional laboratory normal.
  • Newly diagnosed as well as previously treated patients will be eligible.

排除标准

  • History of clinically significant liver or kidney disease.
  • Patients on anti-coagulation therapy with Coumadin will be excluded because of the potential garlic interference with metabolism.
  • Patients receiving concomitant chemotherapeutic treatment

结局指标

主要结局

Time to fever and beginning of empiric antibiotic treatment.

时间窗: 0-45 days post chemotherapy

次要结局

  • Documented and culture positive infections.(as above)
  • Kind of infectious organisms and sensitivity to medicines.(as above)
  • Length of infection(as above)
  • Use of growth factors.(as above)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Moshe Gatt

Dr. Moshe Gatt

Hadassah Medical Organization

研究点 (1)

Loading locations...

相似试验